Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02876302
Previous Study | Return to List | Next Study

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02876302
Recruitment Status : Active, not recruiting
First Posted : August 23, 2016
Last Update Posted : June 24, 2021
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
Filipa Lynce, Dana-Farber Cancer Institute

Tracking Information
First Submitted Date  ICMJE August 9, 2016
First Posted Date  ICMJE August 23, 2016
Last Update Posted Date June 24, 2021
Actual Study Start Date  ICMJE April 26, 2017
Estimated Primary Completion Date February 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 22, 2016)
Assess JAK Inhibition With Ruxolitinib On pStat3+ Expression [ Time Frame: 7 days ]
Comparison of JAK expression in pretreatment biopsy specimens to post-Ruxolitinib run-in (after 7 days of Ruxolitinib alone or with one dose of weekly paclitaxel) biopsy specimens.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 30, 2017)
  • Determine Pathologic Complete Response rate (pCR) after preoperative therapy [ Time Frame: 28 weeks ]
    pCR defined as absence of invasive carcinoma within the breast and axillary lymph nodes following preoperative therapy.
  • Correlate effects on pSTAT3+ and STAT3 gene expression with pCR [ Time Frame: 28 weeks ]
    assess pSTAT level and gene expression on pre-treatment tumor biopsy specimens and correlate expression with pCR
  • Assess changes in pSTAT3 level and STAT3 gene expression following treatment [ Time Frame: 28 weeks ]
    assess pSTAT level and gene expression on pre-treatment tumor biopsy
  • Asses difference in pCR rate following preoperative treatment [ Time Frame: 28 weeks ]
    pCR defined as absence of invasive carcinoma within the breast and axillary lymph nodes following preoperative therapy.
  • Determine efficacy defined as Disease-Free Survival (DFS) [ Time Frame: 5 years ]
    Defined as time of surgery until occurrence of recurrence, contralateral cancer, death attributable to any cause, second primary cancer other than breast.
  • Determine efficacy defined as Time to Treatment Failure (TTF) [ Time Frame: 5 years ]
    Defined as time of treatment initiation until occurrence of recurrence, contralateral cancer, death attributable to any cause, second primary cancer other than breast or occurrence of progressive disease during preoperative therapy or treatment of disease that is not surgically resectable.
  • Determine efficacy defined as Overall Survival (OS) [ Time Frame: 5 years ]
    Defined as time from surgery until death from any cause or from treatment initiation until death from any cause
  • Assess Residual Cancer Burden (RCB) differences after preoperative therapy [ Time Frame: 5 years ]
    Difference between combination ruxolitinib with paclitaxel or paclitaxel alone followed by doxorubicin/cyclophosphamide; RCB defined by Symmans et al
  • Describe changes in IL-6 plasma levels during treatment [ Time Frame: 5 years ]
    IL-6 levels will be recorded in the case report forms.
  • Describe changes in CRP plasma levels during treatment [ Time Frame: 5 years ]
    CRP levels will be recorded in the case report forms.
  • Assess distribution of CD44+/CD24- stem cell population in tumor pre- and post-exposure to ruxolotinib [ Time Frame: 5 years ]
    Performed on breast biopsies and residual disease in mastectomy specimens
Original Secondary Outcome Measures  ICMJE
 (submitted: August 22, 2016)
  • Determine Pathologic Complete Response rate (pCR) after preoperative therapy [ Time Frame: 28 weeks ]
    pCR defined as absence of invasive carcinoma within the breast and axillary lymph nodes following preoperative therapy.
  • Correlate effects on pSTAT3+ and STAT3 gene expression with pCR [ Time Frame: 28 weeks ]
    assess pSTAT level and gene expression on pre-treatment tumor biopsy specimens and correlate expression with pCR
  • Assess changes in pSTAT3 level and STAT3 gene expression following treatment [ Time Frame: 28 weeks ]
    assess pSTAT level and gene expression on pre-treatment tumor biopsy
  • Asses difference in pCR rate following preoperative treatment [ Time Frame: 28 weeks ]
    pCR defined as absence of invasive carcinoma within the breast and axillary lymph nodes following preoperative therapy.
  • Determine efficacy defined as Disease-Free Survival (DFS) [ Time Frame: 5 years ]
    Defined as time of surgery until occurrence of recurrence, contralateral cancer, death attributable to any cause, second primary cancer other than breast.
  • Determine efficacy defined as Time to Treatment Failure (TTF) [ Time Frame: 5 years ]
    Defined as time of treatment initiation until occurrence of recurrence, contralateral cancer, death attributable to any cause, second primary cancer other than breast or occurrence of progressive disease during preoperative therapy or treatment of disease that is not surgically resectable.
  • Determine efficacy defined as Overall Survival (OS) [ Time Frame: 5 years ]
    Defined as time from surgery until death from any cause or from treatment initiation until death from any cause
  • Assess Residual Cancer Burden (RCB) differences after preoperative therapy [ Time Frame: 5 years ]
  • Describe changes in IL-6 plasma levels during treatment [ Time Frame: 5 years ]
    IL-6 levels will be recorded in the case report forms.
  • Describe changes in CRP plasma levels during treatment [ Time Frame: 5 years ]
    CRP levels will be recorded in the case report forms.
  • Assess distribution of CD44+/CD24- stem cell population in tumor pre- and post-exposure to ruxolotinib [ Time Frame: 5 years ]
    Performed on breast biopsies and residual disease in mastectomy specimens
  • Assess pSTAT level and STAT3gene expression when ruxolitinib is withdrawn [ Time Frame: 5 years ]
    assess pSTAT level and gene expression on pre-treatment tumor biopsy specimen, run-in biopsy specimen, and any residual tumor at time of surgical resection
  • Asses pSTAT3 level and STAT3 gene expression after combination ruxolitinib with paclitaxel [ Time Frame: 5 years ]
    assess pSTAT level and gene expression on tumor biopsy specimens
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Official Title  ICMJE Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Brief Summary

This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC).

The Following drugs will be use in combination with Ruxolinitinib.

  • Paclitaxel (also called Taxol)
  • Doxorubicin also called Adriamycin
  • Cyclophosphamide, also called Cytoxan
Detailed Description

This is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

The FDA (U.S. Food and Drug Administration) has not approved Ruxolitinib for Inflammatory Breast Cancer (IBC), but is has been approved for other uses.

Ruxolitinib is a newly discovered drug that has been shown to block a pathway (called the IL6/JAK/Stat pathway) that may be important in cancer, including triple negative inflammatory breast cancer. Ruxolitinib brings proteins groups together, which can result in gene (DNA) changes. These DNA changes may stop cancer cells from growing.

Paclitaxel (also called Taxol), Doxorubicin and Cyclophosphamide (also called Adriamycin and Cytoxan, ("AC")) are drugs FDA approved for breast cancer patients. They have been shown to result in death of cancer cells when given as preoperative treatment of women with inflammatory breast cancer (IBC). Laboratory studies have shown that Ruxolitinib may make Paclitaxel more effective.

In this research study, the investigators are evaluating Ruxolitinib in combination with Paclitaxel followed by the standard chemotherapy, AC. Researchers will also evaluate how the IL6/JAK/Stat pathway is affected by this combination of drugs by studying biopsies and surgical specimens.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Inflammatory Breast Cancer (IBC)
Intervention  ICMJE
  • Drug: Ruxolitinib
    15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.
    Other Name: Jakafi
  • Drug: Paclitaxel
    80 mg/m2, IV (in the vein) weekly for 12 weeks.
    Other Name: Taxol
  • Drug: Doxorubicin
    60 mg/m2, IV (in the vein) every 14 days for 4 doses.
    Other Name: Adriamycin
  • Drug: Cyclophosphamide
    600 mg/m2, IV (in the vein) every 14 days for 4 doses.
    Other Name: Cytoxan
Study Arms  ICMJE
  • Experimental: Paclitaxel (12weeks)

    Paclitaxel is administered weekly followed by standard Doxorubicin and Dyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively

    • 16 patients will be randomized from the Run-In 7 days of Ruxolitinib
    • The drug will be administered at a pre-determine dosage
    Interventions:
    • Drug: Ruxolitinib
    • Drug: Paclitaxel
    • Drug: Doxorubicin
    • Drug: Cyclophosphamide
  • Experimental: Ruxolitinib with Paclitaxel (12weeks)

    Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively

    • 16 patients will be randomized from the Run-In 7 days of Ruxolitinib
    • The drug will be administered at a pre-determine dosage
    Interventions:
    • Drug: Ruxolitinib
    • Drug: Paclitaxel
    • Drug: Doxorubicin
    • Drug: Cyclophosphamide
  • Experimental: Ruxolitinib and Paclitaxel (12weeks)

    Paclitaxel is administered with daily Ruxolitinib, followed by standard Doxorubicin and Cyclophosphamide (AC) given every 2 weeks for 4 cycles preoperatively

    • 32 patients will be randomized from the Run-In 7 days of Ruxolitinib + Paclitaxel
    • The drug will be administered at a pre-determine dosage
    Interventions:
    • Drug: Ruxolitinib
    • Drug: Paclitaxel
    • Drug: Doxorubicin
    • Drug: Cyclophosphamide
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: May 11, 2021)
23
Original Estimated Enrollment  ICMJE
 (submitted: August 22, 2016)
64
Estimated Study Completion Date  ICMJE February 2024
Estimated Primary Completion Date February 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Participants must have histologically confirmed invasive breast cancer. All histologic subtypes are eligible.
  • Patients must have known ER, PR, and HER2 status defined as triple-negative breast cancer (TNBC), defined as:

    --ER and PR <10% by immunohistochemistry, and HER2-negative ( as per ASCO/CAP guidelines, defined as IHC 0 or 1+, or FISH ratio <2.0 or HER2 copy number <6.0).

  • Patients must have the clinical diagnosis of inflammatory breast cancer, involving an intact breast.
  • Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of ruxolitinib in participants <18 years of age, children are excluded from this study.
  • ECOG performance status 0 or 1.
  • Participants must have normal organ and marrow function as defined below:

    • Leukocytes ≥ 3,000/mm3
    • Absolute neutrophil count ≥ 1,500/mm3
    • Platelets ≥ 100,000/mm3
    • Bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
    • AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal
    • Creatinine ≤1.5 x institutional upper limit of normal OR creatinine clearance > 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal
  • Patients with evidence of extensive nodal involvement are allowed. Extensive nodal involvement is defined as metastatic disease involving any nodal region outside of the involved breast.
  • Patients with minimal metastatic disease involvement in bone or viscera are allowed. Minimal metastatic disease is defined as: evidence of metastatic involvement as demonstrated by imaging only, not amenable to biopsy confirmation.
  • Both men and women are allowed.
  • The effects of ruxolitinib on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry until completion of chemotherapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • Ability to understand and the willingness to sign a written informed consent document.
  • LVEF > 50% calculated by echocardiogram (ECHO) or MUGA
  • Patients may have bilateral breast cancer so long as one breast meets criteria for inflammatory breast cancer, and neither breast cancer has received prior therapy

Exclusion Criteria:

  • Participants may not be receiving any other investigational agents.
  • Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib.
  • Participants receiving any medications or substances that are potent inhibitors of CYP3A4, including grapefruit juice are ineligible. Participants receiving fluconazole are also ineligible. (Please refer to Appendix B for the full list of potent inhibitors and washout periods).
  • Chronic corticosteroid use in excess of the equivalent of prednisone 10 mg once daily.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study because paclitaxel, doxorubicin, and cyclophosphamide have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is treated on study. These potential risks may also apply to other agents used in this study.
  • Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
  • Known HIV-positive individuals on combination antiretroviral therapy are eligible so long as they meet all other criteria. Known HIV-positive individuals who are not on combination antiretroviral therapy are not eligible because these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
  • Clinically significant malabsorption syndrome.
  • Patients may not have received paclitaxel, doxorubicin, or cyclophosphamide as anti-neoplastic therapy.
  • Patients with prior radiation to the affected breast.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02876302
Other Study ID Numbers  ICMJE 16-151
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Filipa Lynce, Dana-Farber Cancer Institute
Study Sponsor  ICMJE Dana-Farber Cancer Institute
Collaborators  ICMJE Incyte Corporation
Investigators  ICMJE
Principal Investigator: Filipa Lynce, MD Dana-Farber Cancer Institute
PRS Account Dana-Farber Cancer Institute
Verification Date June 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP